Estrogen and Fear (PTSD)

  • STATUS
    Recruiting
  • End date
    Nov 15, 2022
  • participants needed
    80
  • sponsor
    NYU Langone Health
Updated on 15 July 2020
benzodiazepines

Summary

The purpose of this research study is to determine if taking a pill of estradiol (E2) together with prolonged exposure (PE) therapy can improve this treatment outcome in women diagnosed with Post-Traumatic Stress Disorder (PTSD). 80 subjects will take part in this research study across NYU Langone Health and UPenn (40 subjects at each site). Participants will be randomized into one of two groups, PE + E2 or PE + placebo. The study will include preliminary screening and baseline visits, experimental visits, and therapy visits over the course of six weeks. Several follow-up visits will take place.

Description

Prolonged-exposure (PE) therapy is the treatment of choice for posttraumatic stress disorder (PTSD). Despite its efficacy, a significant number of individuals will not benefit from it or might drop out before the completion of all sessions. This underlies the importance of findings ways to enhance the efficacy of PE in order to improve the life quality of individuals suffering from PTSD. It is now widely accepted that extinction learning paradigms used in fundamental studies are useful laboratory analogs to PE. Studies in healthy controls have suggested that elevated estrogen levels benefit extinction learning by promoting its consolidation and thus enhancing its recall when tested later for it. This is also being reflected by changes in the activation of brain regions forming the fear extinction network, including the amygdala, dorsal anterior cingulate cortex (dACC) and ventromedial prefrontal cortex (vmPFC). It is still unknown whether estradiol (E2) administration can modulate the activation of the fear extinction network in oral contraceptive (OC) users and which E2 dose could yield the best results. During the R61 phase of the study, we found that both doses of E2 were effective in engaging the functional activation of the fear extinction network. Therefore, we will use the lower dose (2mg) for the R33 phase. We will combine E2 administration with PE sessions to see if administration of PE can significantly improve clinical outcomes (reduced PTSD symptoms) and engage the fear extinction network in the brain.

Hypothesis: A general improvement is expected after 3 weeks of treatment in both groups given the anticipated benefits of PE alone. But the benefit of the Estradiol-treated groups is hypothesized be larger; with this group exhibiting significantly higher activation in brain regions associated with fear extinction. This will be noted at the follow-up scan compared to the baseline scan.

PTSD symptom severity expected be significantly lower in the Estradiol and PE group relative to the Placebo+PE group following acute treatment after three weeks of treatment.

The degree of PTSD symptom reduction post- compared to pre-PE after 3 weeks of treatment is expected be associated with BOLD changes in the fear extinction network and reduction in SCR during the extinction recall test after PE. The magnitude of BOLD and SCR changes will be significantly larger in the E2+PE group compared to the Plc+PE group.

Details
Condition Post-Traumatic Stress Disorder, Post-Traumatic Stress Disorders, healthy, Post-Traumatic Stress Disorders
Treatment Placebo, Estradiol
Clinical Study IdentifierNCT03371654
SponsorNYU Langone Health
Last Modified on15 July 2020

Eligibility

Yes No Not Sure

Inclusion Criteria

Female, 18-45 years of age
Chronic (at least three months post-trauma) DSM-5 PTSD symptoms
CAPS-5 score 26
Criterion A traumatic event
Symptoms include at least one re-experiencing symptom, at least one avoidance symptom, at least two cognition and mood symptoms, and at least two hyperarousal symptoms
Right-handed (Edinburgh Inventory - Oldfield 1971)
Literate in English
Psychiatric medications (with the exception of benzodiazepines) will be allowed if stable for at least 3 months prior to study baseline. Benzodiazepine use will be excluded
Women on oral contraceptives, specifically those using monophasic of first, second, third or fourth generation with 20mcg of ethinyl estradiol or willingness to start taking oral contraceptives
Willing and able to provide informed consent

Exclusion Criteria

Other primary diagnoses (e.g., pervasive developmental disorders, psychotic disorder, thought disorder, conduct disorder, or presence of other disorder that is primary relative to PTSD)
Suicidal ideation with intent
Concurrent trauma focused psychotherapy
Pregnancy (to be ruled out by urine -HCG)
Metallic implants or devices contraindicating magnetic resonance imaging
History of breast cancer or hormone-responsive cancer
Allergy to peanut oil
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note